Abstracts tagged "Cutaneous lupus erythematosus"

Abstract Number: 428 • 2019 ACR/ARP Annual Meeting
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
Srita Chakka¹, Rebecca Krain ¹, Sarah Ahmed ², Josef Concha ¹, Rui Feng ³ and Victoria Werth ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL).…
Abstract Number: 664 • 2019 ACR/ARP Annual Meeting
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus
Wietske Lambers¹, Karina de Leeuw ², Femke Homan ¹, Berber Doornbos-van der Meer ¹, Hendrika Bootsma ³, Johanna Westra ² and Gilles Diercks ¹, ¹UMCG, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous auto-inflammatory skin disease, that is driven to a great extent by interferon (IFN) type I1, and is…
Abstract Number: 1939 • 2019 ACR/ARP Annual Meeting
Analysis of Discoid Lupus Erythematosus (DLE) Gene Expression Reveals Dysregulation of Pathogenic Pathways Associated with Infiltrating Immune/Inflammatory Cells
Frances Harris¹, Sarah Heuer ², Robert Robl ², Prathyusha Bachali ², Adam Labonte ², Benjamin Chong ³, Michelle Catalina ², Peter Lipsky ² and Amrie Grammer ², ¹RILITE Research Institute, Charlottesville, VA, ²RILITE Research Institute, Charlottesville, ³University of Texas Southwestern, Dallas
Background/Purpose: DLE is a chronic, scarring inflammatory autoimmune disease of the skin. The precise molecular pathways underlying DLE pathogenesis have not been fully delineated. To…
Abstract Number: 2040 • 2019 ACR/ARP Annual Meeting
BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes
Jessica Turnier¹, Celine Berthier ¹, Lam Tsoi ¹, Danielle Barnes ¹, Grace Hile ¹, Tamra Reed ¹, Jianhua Liu ¹, Johann Gudjonsson ¹ and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation can drive systemic disease in SLE, thus it is essential to understand the key regulators of the aberrant inflammatory response in lupus…
Abstract Number: 876 • 2018 ACR/ARHP Annual Meeting
Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease
Tori Nault¹, Alex Tsoi², Tamra J. Reed³, Mehrnaz Gharaee-Kermani³, Lori Lowe⁴, Johann Gudjonsson⁴ and Michelle Kahlenberg³, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Dermatomyositis (DM) is a rare disease with both cutaneous and muscle pathophysiology. In the skin of DM patients, very little is known about the…
Abstract Number: 1399 • 2018 ACR/ARHP Annual Meeting
Assessing a Conceptual Framework of Quality of Life in a Cutaneous Lupus Erythematosus Population
Motolani E. Ogunsanya¹, Andrew Hudson², Rebecca Vasquez³ and Benjamin F. Chong³, ¹College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In order to better discern medication efficacy for CLE, a better understanding of CLE’s impact on quality of life (QoL) in individuals with CLE…
Abstract Number: 1896 • 2018 ACR/ARHP Annual Meeting
Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
Alex Tsoi¹, Grace Hile², Celine C. Berthier³, Mrinal Sarkar⁴, Tamra J. Reed⁵, Ranjitha Uppala⁴, Matthew Patrick⁴, Kalpana Raja⁴, Xianying Xing⁶, Kevin He², Johann Gudjonsson⁴ and Michelle Kahlenberg⁷, ¹Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Dermatology, University of Michigan, University of Michigan, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous…
Abstract Number: 2112 • 2018 ACR/ARHP Annual Meeting
IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE
Stephanie Lazar¹, Rajaie Namas², Celine C. Berthier³ and Michelle Kahlenberg⁴, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with SLE have increased type I IFN-regulated gene expression in peripheral blood, which has been correlated with systemic disease activity. IFN-regulated gene expression…
Abstract Number: 2114 • 2018 ACR/ARHP Annual Meeting
Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes
Grace Hile¹, Mrinal Sarkar², Jianhua Liu³, Tamra J. Reed⁴, Johann Gudjonsson² and Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²Dermatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Photosensitivity, defined as increased cutaneous erythema and inflammation after ultraviolet light (UV) exposure, is a hallmark of patients with systemic lupus erythematosus (SLE), cutaneous…
Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting
Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally
Taylor L. Reynolds¹, Carrie Wager¹, Stefan Hamann¹, Xueli Zhang¹, Galina Marsh¹, Cristina Musselli¹, Nathalie Franchimont¹, Agnes Gardet¹, Robert Dunstan², Dania Rabah¹ and Victoria P Werth³, ¹Biogen, Cambridge, MA, ²Abbvie, Worcester, MA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…
Abstract Number: 1613 • 2017 ACR/ARHP Annual Meeting
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus on Standard of Care Treatments Using Longitudinal Registries from Two Academic Dermatology Centers
Noelle M. Teske¹, Khor Jia Ker^2,3, Rui Feng⁴, Benjamin F. Chong¹ and Victoria P Werth⁵, ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Dermatology, National Skin Centre, Singapore, Singapore, ³Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania and the VA Medical Center, Philadelphia, PA
Background/Purpose: The natural disease course of patients with cutaneous lupus erythematosus (CLE) on standard-of-care treatments is not fully characterized. We sought to characterize their disease…
Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Lavanya Mittal¹, Lingqiao Zhang², Rui Feng² and Victoria Werth¹, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
Abstract Number: 2626 • 2017 ACR/ARHP Annual Meeting
Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes
Yih Jia Poh¹, Shirish Sangle¹, Eleanor Higgins¹, Emma Benton¹, David McGibbon¹ and David D'Cruz², ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Drug induced subacute cutaneous lupus erythematosus has rarely been described. There is a growing literature reporting the association between proton pump inhibitor use and…
Abstract Number: 1118 • 2016 ACR/ARHP Annual Meeting
Increased Population of Myeloid Dendritic Cells and Upregulated Gene Expression of Tnfα Is Associated with Poor Response to Hydroxychloroquine
Majid Zeidi^1,2, Hee Joo Kim^1,3,4 and Victoria P. Werth^1,3, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, The Republic of
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and wide-ranging clinical manifestations. T lymphocytes are the predominant cell type found in…
Abstract Number: 1186 • 2016 ACR/ARHP Annual Meeting
The Use of Clinical Mucosal Manifestations to Differentiate Patients with Lupus and Dermatomyositis: Transversal, Retrospective and Analytical Study of 116 Patients
Cristián Vera-Kellet Sr., Pablo del Barrio-Díaz Sr., Jorge Manríquez-Moreno Sr. and Carlos Reyes-Vivanco Sr., Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: There are few studies comparing oral manifestations in patients with Cutaneous Lupus (CL), Systemic Lupus Erythematosus (SLE) and Dermatomyositis (DM). Our objective was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].